CA3088984A1 - Closed-ended dna vectors obtainable from cell-free synthesis and process for obtaining cedna vectors - Google Patents
Closed-ended dna vectors obtainable from cell-free synthesis and process for obtaining cedna vectors Download PDFInfo
- Publication number
- CA3088984A1 CA3088984A1 CA3088984A CA3088984A CA3088984A1 CA 3088984 A1 CA3088984 A1 CA 3088984A1 CA 3088984 A CA3088984 A CA 3088984A CA 3088984 A CA3088984 A CA 3088984A CA 3088984 A1 CA3088984 A1 CA 3088984A1
- Authority
- CA
- Canada
- Prior art keywords
- itr
- sequence
- sense
- expression cassette
- stranded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/103—Plasmid DNA for invertebrates
- C12N2800/105—Plasmid DNA for invertebrates for insects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/60—Vectors comprising a special origin of replication system from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862619392P | 2018-01-19 | 2018-01-19 | |
| US62/619,392 | 2018-01-19 | ||
| PCT/US2019/014122 WO2019143885A1 (en) | 2018-01-19 | 2019-01-18 | Closed-ended dna vectors obtainable from cell-free synthesis and process for obtaining cedna vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3088984A1 true CA3088984A1 (en) | 2019-07-25 |
Family
ID=67301565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3088984A Pending CA3088984A1 (en) | 2018-01-19 | 2019-01-18 | Closed-ended dna vectors obtainable from cell-free synthesis and process for obtaining cedna vectors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12442015B2 (enExample) |
| EP (1) | EP3740571A4 (enExample) |
| JP (3) | JP2021511047A (enExample) |
| KR (2) | KR102879598B1 (enExample) |
| CN (1) | CN111868242A (enExample) |
| AU (1) | AU2019210034B2 (enExample) |
| BR (1) | BR112020013319A2 (enExample) |
| CA (1) | CA3088984A1 (enExample) |
| IL (1) | IL275878B2 (enExample) |
| MA (1) | MA51626A (enExample) |
| MX (1) | MX2020005790A (enExample) |
| MY (1) | MY208589A (enExample) |
| PH (1) | PH12020550878A1 (enExample) |
| SG (1) | SG11202005271TA (enExample) |
| UA (1) | UA130154C2 (enExample) |
| WO (1) | WO2019143885A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020002394A2 (pt) | 2017-08-09 | 2020-07-28 | Bioverativ Therapeutics Inc. | moléculas de ácidos nucleicos e usos das mesmas |
| MA51842A (fr) * | 2018-02-14 | 2020-12-23 | Generation Bio Co | Vecteurs d'adn non viraux et utilisations associées pour la production d'anticorps et de protéines de fusion |
| KR102925832B1 (ko) | 2018-08-09 | 2026-02-11 | 바이오버라티브 테라퓨틱스 인크. | 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도 |
| AU2019376663A1 (en) * | 2018-11-09 | 2021-06-24 | Generation Bio Co. | Modified closed-ended DNA (ceDNA) comprising symmetrical modified inverted terminal repeats |
| GB201905651D0 (en) | 2019-04-24 | 2019-06-05 | Lightbio Ltd | Nucleic acid constructs and methods for their manufacture |
| CA3147414A1 (en) | 2019-07-17 | 2021-01-21 | Generation Bio Co. | Synthetic production of single-stranded adeno associated viral dna vectors |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| AU2021244555A1 (en) * | 2020-03-24 | 2022-11-24 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing factor ix therapeutics |
| WO2022023284A1 (en) * | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| US20220243201A1 (en) * | 2020-08-23 | 2022-08-04 | Bioverativ Therapeutics Inc. | Engineered itr sequences and methods of use |
| EP4214309A4 (en) * | 2020-09-16 | 2025-07-16 | Generation Bio Co | CLOSED-END DNA VECTORS AND RELATED USES FOR EXPRESSING PHENYLALANINE HYDROXYLASE (PAH) |
| GB202014751D0 (en) | 2020-09-18 | 2020-11-04 | Lightbio Ltd | Targeting vector |
| GB202014772D0 (en) | 2020-09-18 | 2020-11-04 | Lightbio Ltd | Nucleic acid construct |
| TW202246499A (zh) * | 2021-01-25 | 2022-12-01 | 美商普維爾治療公司 | 以腺相關病毒（ａａｖ）為基礎的基因表現之調節 |
| CN112980862A (zh) * | 2021-02-25 | 2021-06-18 | 通用生物系统（安徽）有限公司 | 一种高纯度微环dna的制备方法 |
| US20240358852A1 (en) | 2021-04-20 | 2024-10-31 | Anjarium Biosciences Ag | Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof |
| EP4329884A1 (en) * | 2021-04-27 | 2024-03-06 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
| WO2022232289A1 (en) * | 2021-04-27 | 2022-11-03 | Generation Bio Co. | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
| KR20240005903A (ko) * | 2021-05-07 | 2024-01-12 | 제너레이션 바이오 컴퍼니 | 백신 전달을 위한 비바이러스성 dna 벡터 |
| US20240261395A1 (en) * | 2021-05-07 | 2024-08-08 | Generation Bio Co. | Lyophilized non-viral dna vector compositions and uses thereof |
| CN118489008A (zh) * | 2021-12-23 | 2024-08-13 | 世代生物公司 | 封闭端dna载体的可扩展且高纯度无细胞合成 |
| JP2025504404A (ja) | 2022-01-14 | 2025-02-12 | アンジャリウム バイオサイエンシズ エージー | Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法 |
| GB202204112D0 (en) | 2022-03-23 | 2022-05-04 | Lightbio Ltd | Linear construct |
| EP4293101A1 (en) | 2022-06-14 | 2023-12-20 | Asklepios Biopharmaceutical, Inc. | Reactor with temperature control and method of using the same |
| EP4558637A2 (en) | 2022-07-19 | 2025-05-28 | Rampart Bioscience, Inc. | Non-immunogenic circular, non-viral dna vectors |
| US20260055426A1 (en) | 2022-08-19 | 2026-02-26 | Generation Bio Co. | CLEAVABLE CLOSED-ENDED DNA (ceDNA) AND METHODS OF USE THEREOF |
| WO2024119017A1 (en) * | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Synthetic single stranded nucleic acid compositions and methods thereof |
| WO2024170778A1 (en) | 2023-02-17 | 2024-08-22 | Anjarium Biosciences Ag | Methods of making dna molecules and compositions and uses thereof |
| US11993783B1 (en) | 2023-03-27 | 2024-05-28 | Genecraft Inc. | Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof |
| WO2026085495A1 (en) | 2024-10-18 | 2026-04-23 | Generation Bio Co. | Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
| EP1463761A1 (en) | 2001-11-30 | 2004-10-06 | Innogenetics N.V. | Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma |
| JP4997253B2 (ja) | 2007-08-10 | 2012-08-08 | Ｔｏｔｏ株式会社 | 組換え哺乳動物細胞、組換え哺乳動物細胞の製造方法、および目的タンパク質の生産方法 |
| US8709778B2 (en) * | 2008-10-28 | 2014-04-29 | Xavier Danthinne | Method of adenoviral vector synthesis |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| EP3517612A1 (en) | 2013-03-15 | 2019-07-31 | The University of North Carolina At Chapel Hill | Synthetic adeno-associated virus inverted terminal repeats |
| SG10201913688TA (en) * | 2016-03-03 | 2020-03-30 | Univ Massachusetts | Closed-ended linear duplex dna for non-viral gene transfer |
| AU2018371063C1 (en) | 2017-11-21 | 2025-04-17 | 4basebio Sl | Methods and kits for amplification of double stranded DNA |
| MA51842A (fr) * | 2018-02-14 | 2020-12-23 | Generation Bio Co | Vecteurs d'adn non viraux et utilisations associées pour la production d'anticorps et de protéines de fusion |
| MX2021008874A (es) * | 2019-01-24 | 2021-08-19 | Generation Bio Co | Adn de extremo cerrado (ceadn) y uso en metodos de reduccion de la respuesta inmunitaria relacionada con tratamiento genico o de acido nucleico. |
| CA3147414A1 (en) * | 2019-07-17 | 2021-01-21 | Generation Bio Co. | Synthetic production of single-stranded adeno associated viral dna vectors |
| US20220228171A1 (en) * | 2019-07-17 | 2022-07-21 | Generation Bio Co. | Compositions and production of nicked closed-ended dna vectors |
-
2019
- 2019-01-18 US US16/962,005 patent/US12442015B2/en active Active
- 2019-01-18 MA MA051626A patent/MA51626A/fr unknown
- 2019-01-18 SG SG11202005271TA patent/SG11202005271TA/en unknown
- 2019-01-18 CN CN201980019414.XA patent/CN111868242A/zh active Pending
- 2019-01-18 EP EP19741445.1A patent/EP3740571A4/en active Pending
- 2019-01-18 JP JP2020539779A patent/JP2021511047A/ja active Pending
- 2019-01-18 MX MX2020005790A patent/MX2020005790A/es unknown
- 2019-01-18 CA CA3088984A patent/CA3088984A1/en active Pending
- 2019-01-18 AU AU2019210034A patent/AU2019210034B2/en active Active
- 2019-01-18 KR KR1020207023526A patent/KR102879598B1/ko active Active
- 2019-01-18 KR KR1020257036119A patent/KR20250159738A/ko active Pending
- 2019-01-18 UA UAA202005240A patent/UA130154C2/uk unknown
- 2019-01-18 BR BR112020013319-1A patent/BR112020013319A2/pt unknown
- 2019-01-18 MY MYPI2020003241A patent/MY208589A/en unknown
- 2019-01-18 WO PCT/US2019/014122 patent/WO2019143885A1/en not_active Ceased
- 2019-01-18 IL IL275878A patent/IL275878B2/en unknown
-
2020
- 2020-06-11 PH PH12020550878A patent/PH12020550878A1/en unknown
-
2023
- 2023-07-14 JP JP2023116157A patent/JP2023126487A/ja not_active Withdrawn
-
2025
- 2025-05-21 JP JP2025084944A patent/JP2025113389A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200111726A (ko) | 2020-09-29 |
| WO2019143885A1 (en) | 2019-07-25 |
| IL275878B1 (en) | 2025-11-01 |
| BR112020013319A2 (pt) | 2020-12-01 |
| MY208589A (en) | 2025-05-19 |
| PH12020550878A1 (en) | 2021-04-05 |
| EP3740571A1 (en) | 2020-11-25 |
| JP2023126487A (ja) | 2023-09-07 |
| EP3740571A4 (en) | 2021-12-08 |
| CN111868242A (zh) | 2020-10-30 |
| IL275878B2 (en) | 2026-03-01 |
| KR102879598B1 (ko) | 2025-11-03 |
| IL275878A (en) | 2020-08-31 |
| MX2020005790A (es) | 2020-10-28 |
| JP2025113389A (ja) | 2025-08-01 |
| KR20250159738A (ko) | 2025-11-11 |
| MA51626A (fr) | 2020-11-25 |
| RU2020127017A (ru) | 2022-02-21 |
| SG11202005271TA (en) | 2020-07-29 |
| AU2019210034B2 (en) | 2025-03-27 |
| US12442015B2 (en) | 2025-10-14 |
| AU2019210034A1 (en) | 2020-07-09 |
| US20210071197A1 (en) | 2021-03-11 |
| JP2021511047A (ja) | 2021-05-06 |
| UA130154C2 (uk) | 2025-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12442015B2 (en) | Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectors | |
| US12577573B2 (en) | Synthetic production of single-stranded adeno associated viral DNA vectors | |
| JP7590963B2 (ja) | 対称的な修飾型逆位末端反復配列を含む修飾型閉端ｄｎａ（ｃｅｄｎａ） | |
| US20200283794A1 (en) | Modified closed-ended dna (cedna) | |
| US20220175970A1 (en) | Controlled expression of transgenes using closed-ended dna (cedna) vectors | |
| US20220228171A1 (en) | Compositions and production of nicked closed-ended dna vectors | |
| CA3133330A1 (en) | Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics | |
| CA3172591A1 (en) | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics | |
| US20250049961A1 (en) | Scalable and high-purity cell-free synthesis of closed-ended dna vectors | |
| CA3191765A1 (en) | Closed-ended dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220923 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250110 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250110 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250110 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250612 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251014 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251210 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251210 |